The EMA has approved Penbraya for protection against invasive meningococcal disease and an update of the composition of two ...

Targeting two receptors instead of the one targeted by fezolinetant, the new elinzanetant did not show the liver safety ...

Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at ...

The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on Wednesday, ...

Pfizer is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug ...

As you can see below, at the end of June 2024, Pfizer had US$69.9b of debt, up from US$65.7b a year ago. Click the image for ...

PFE's non-COVID drugs and potential contribution from new and newly acquired products have started to drive growth.

State Surgeon General Joseph Ladapo spread anti-vaccine misinformation by telling Floridians to avoid mRNA vaccines. Vaccine ...

Discover Vicebio's molecular clamp technology as it completes a $100 million series B round for its bivalent vaccine against ...

Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer ...

Pfizer's and Moderna's formulas have been the go-to on pharmacy shelves, but Novavax remains an important option.

The company's best days as a top pandemic vaccine supplier might be over, but it still has enough potential to be compelling.